Johnson & Johnson vaccine: Why has the US been told to pause J&J Covid vaccine rollout?

When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. Our Privacy Notice explains more about how we use your data, and your rights. You can unsubscribe at any time.

Johnson & Johnson is the first company to produce an effective single-dose vaccine against coronavirus. But, US officials have recommended the vaccine rollout be paused while it reviews reports of rare blood clots in people that recently received the jab.

The FDA official Twitter account tweeted: “Today FDA and @CDCgov issued a statement regarding the Johnson & Johnson #COVID19 vaccine. We are recommending a pause in the use of this vaccine out of an abundance of caution.

“As of 4/12, 6.8m+ doses of the J&J vaccine have been administered in the US. CDC & FDA are reviewing data involving 6 reported US cases of a rare & severe type of blood clot in individuals after receiving the vaccine. Right now, these adverse events appear to be extremely rare.

“Treatment of this specific type of blood clot is different from the treatment that might typically be administered.

“CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases.

“Until that process is complete, we are recommending this pause. This is important to ensure that the health care provider community is aware of the potential for these adverse events and can plan due to the unique treatment required with this type of blood clot.”

More to follow…

Source: Read Full Article